These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36053463)

  • 21. Diagnostic advantage of double immunohistochemistry using two mutation-specific anti-IDH antibodies (HMab-1 and MsMab-1) in gliomas.
    Takano S; Kato Y; Yamamoto T; Liu X; Ishikawa E; Kaneko MK; Ogasawara S; Matsuda M; Noguchi M; Matsumura A
    Brain Tumor Pathol; 2015 Jul; 32(3):169-75. PubMed ID: 25652153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
    Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J
    World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Classification of gliomas. Current progress and perspectives].
    Capper D; Reifenberger G
    Nervenarzt; 2015 Jun; 86(6):672, 674-6, 678-80, passim. PubMed ID: 25989737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular classification of adult diffuse gliomas: conflicting IDH1/IDH2, ATRX, and 1p/19q results.
    Ballester LY; Huse JT; Tang G; Fuller GN
    Hum Pathol; 2017 Nov; 69():15-22. PubMed ID: 28549927
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Custom DNA-Based NGS Panel for the Molecular Characterization of Patients With Diffuse Gliomas: Diagnostic and Therapeutic Applications.
    Tirrò E; Massimino M; Broggi G; Romano C; Minasi S; Gianno F; Antonelli M; Motta G; Certo F; Altieri R; Manzella L; Caltabiano R; Barbagallo GMV; Buttarelli FR; Magro G; Giangaspero F; Vigneri P
    Front Oncol; 2022; 12():861078. PubMed ID: 35372034
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interlaboratory comparison of IDH mutation detection.
    van den Bent MJ; Hartmann C; Preusser M; Ströbel T; Dubbink HJ; Kros JM; von Deimling A; Boisselier B; Sanson M; Halling KC; Diefes KL; Aldape K; Giannini C
    J Neurooncol; 2013 Apr; 112(2):173-8. PubMed ID: 23358936
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases.
    Na K; Kim HS; Shim HS; Chang JH; Kang SG; Kim SH
    J Neurooncol; 2019 May; 142(3):445-454. PubMed ID: 30710203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utility of real-time polymerase chain reaction for the assessment of CDKN2A homozygous deletion in adult-type IDH-mutant astrocytoma.
    Shimizu Y; Suzuki M; Akiyama O; Ogino I; Matsushita Y; Satomi K; Yanagisawa S; Ohno M; Takahashi M; Miyakita Y; Narita Y; Ichimura K; Kondo A
    Brain Tumor Pathol; 2023 Apr; 40(2):93-100. PubMed ID: 36788155
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.
    Agarwal S; Sharma MC; Jha P; Pathak P; Suri V; Sarkar C; Chosdol K; Suri A; Kale SS; Mahapatra AK; Jha P
    Neuro Oncol; 2013 Jun; 15(6):718-26. PubMed ID: 23486690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A review of adult-type diffuse gliomas in the WHO CNS5 classification with special reference to Astrocytoma, IDH-mutant and Oligodendroglioma, IDH-mutant and 1p/19q codeleted.
    Santosh V; Rao S
    Indian J Pathol Microbiol; 2022 May; 65(Supplement):S14-S23. PubMed ID: 35562130
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Droplet digital PCR-based analyses for robust, rapid, and sensitive molecular diagnostics of gliomas.
    Wolter M; Felsberg J; Malzkorn B; Kaulich K; Reifenberger G
    Acta Neuropathol Commun; 2022 Mar; 10(1):42. PubMed ID: 35361262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats.
    Movassaghi M; Shabihkhani M; Hojat SA; Williams RR; Chung LK; Im K; Lucey GM; Wei B; Mareninov S; Wang MW; Ng DW; Tashjian RS; Magaki S; Perez-Rosendahl M; Yang I; Khanlou N; Vinters HV; Liau LM; Nghiemphu PL; Lai A; Cloughesy TF; Yong WH
    Exp Mol Pathol; 2017 Aug; 103(1):87-93. PubMed ID: 28663030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IDH1 mutation analysis in low cellularity specimen: a limitation of diagnostic accuracy and a proposal for the diagnostic procedure.
    Choi J; Lee EY; Shin KJ; Minn YK; Kim J; Kim SH
    Pathol Res Pract; 2013 May; 209(5):284-90. PubMed ID: 23561624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In-house molecular diagnosis of diffuse glioma updating the revised WHO classification by a platform of the advanced medical care system, Senshin-Iryo.
    Hata N; Fujioka Y; Otsuji R; Kuga D; Hatae R; Sangatsuda Y; Amemiya T; Noguchi N; Sako A; Fujiki M; Mizoguchi M; Yoshimoto K
    Neuropathology; 2024 Oct; 44(5):344-350. PubMed ID: 38477051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular classification of low-grade diffuse gliomas.
    Kim YH; Nobusawa S; Mittelbronn M; Paulus W; Brokinkel B; Keyvani K; Sure U; Wrede K; Nakazato Y; Tanaka Y; Vital A; Mariani L; Stawski R; Watanabe T; De Girolami U; Kleihues P; Ohgaki H
    Am J Pathol; 2010 Dec; 177(6):2708-14. PubMed ID: 21075857
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determination of
    Yaltirik CK; Yilmaz SG; Ozdogan S; Bilgin EY; Barut Z; Ture U; Isbir T
    In Vivo; 2022; 36(4):1694-1702. PubMed ID: 35738587
    [TBL] [Abstract][Full Text] [Related]  

  • 39. WHO CNS5 2021 includes specific mutations in gliomas that can be identified with MRI quantitative biomarkers.
    García-Lezama M; Carrillo-Ruiz JD; Moreno-Jiménez S; Roldán-Valadez E
    Gac Med Mex; 2023; 159(2):161-168. PubMed ID: 37094238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pyrosequencing of IDH1 and IDH2 mutations in brain tumors and non-neoplastic conditions.
    Cykowski MD; Allen RA; Fung KM; Harmon MA; Dunn ST
    Diagn Mol Pathol; 2012 Dec; 21(4):214-20. PubMed ID: 23111198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.